THIRD QUARTER IN BRIEFActive Biotech provided status update for the development of laquinimod in inflammatory eye disorders and tasquinimod in hematological malignancies (July 8)Active Biotech present ...
Ultragenyx Pharmaceutical (RARE) remains unprofitable, with net losses expanding at an average annual rate of 14.8% over the past five years. Even as the company’s profit margin has yet to turn ...
Carlton, Millenia Singapore is pleased to announce the Southeast Asia debut of innovative, science-driven skincare brand EPICUTIS®, developed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback